Table 7.

Independent factors associated with the recurrence of HCC after DAA treatment in the late phase (more than 1 year after DAA treatment completion) according to Cox proportional hazard model analysis

	Hazard ratio	95% CI	p-value
Post-treatment eGFR (mL/min/1.73 m2)	0.98	0.96–0.99	0.032

Data are expressed as means ± standard deviation

ALT alanine aminotransferase; AST aspartate aminotransferase; AFP α-fetoprotein; eGFR estimated glomerular filtration rate; FIB-4 fibrosis-4; APRI AST to platelet ratio index; SVR sustained viral response; BCLC Barcelona Clinic Liver Cancer; CI confidence interval